✦ LIBER ✦

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from the randomized treatment withdrawal phase of a phase 3, randomized, controlled trial (ESTEEM 1)

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Apremilast, an oral phosphodiesterase 4

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Long-term safety and tolerability of apr

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Improvements in patient-reported outcome

✍ Vibeke Strand, David Fiorentino, ChiaChi Hu… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 457 KB

CLinical experience acquired with the ef

✍ L. Dubertret; W. Sterry; J.D. Bos; S. Chimenti; S. Shumack; C.G. Larsen; N.H. Sh 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 342 KB

Efficacy and safety of efalizumab in pat

✍ NAYAK, A 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 27 KB

Impact of ustekinumab on health-related

✍ Hidemi NAKAGAWA; Brad SCHENKEL; Mai KATO; Takeshi KATO; Atsuyuki IGARASHI; The J 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 French ⚖ 317 KB